Abstract.
Since cancer is the result of genetic mutations, it should be well suited for correction through gene therapy. Hematological malignancies in which human gene transfer has been performed are leukemias, lymphomas, graft-versushost disease after allogeneic bone marrow transplantation in leukemia, and multiple myeloma. Gene therapy may be used to induce or enhance an antitumor immunological reaction, to correct a genetic defect in the tumor cells, to render the malignant disease more susceptible to conventional therapies, to make the normal host cells more resistant to conventional therapies, or to track cells used for therapy. Gene therapy will probably be most valuable for the eradication of minimal residual disease after the use of conventional therapies.
Article PDF
Similar content being viewed by others
Author information
Authors and Affiliations
Additional information
Received: 10 February 2003 / Accepted: 24 February 2003
Correspondence to I.G.H. Schmidt-Wolf
Rights and permissions
About this article
Cite this article
Schmidt-Wolf, G., Schmidt-Wolf, I. Gene therapy for hematological malignancies. Clin Exp Med 3, 4–14 (2003). https://doi.org/10.1007/s102380300009
Issue Date:
DOI: https://doi.org/10.1007/s102380300009